

**IN THE CLAIMS:**

1-58. (cancelled)

59. (currently amended) A method comprising[;]:

a) providing[;]:

i) a human patient with symptoms of inflammatory bowel disease, and

ii) a therapeutic formulation comprising antibodies purified from an avian egg yolk, wherein said antibodies are directed to human Tumor Necrosis Factor Alpha;  
and

b) administering said formulation to the lumen of the intestine of said patient under conditions such that at least one of said symptoms is reduced.

60. (previously presented) The method of Claim 59, wherein said avian egg yolk is a chicken egg yolk.

61. (previously presented) The method of Claim 59, wherein said human is a child.

62. (previously presented) The method of Claim 59, wherein said administering reduces said symptoms.

63. (previously presented) The method of Claim 59, wherein said administering is performed rectally.

64. (currently amended) The method of Claim 59, wherein said human has symptoms of ulcerative colitis.

65. (previously presented) The method of Claim 59, wherein said human has symptoms of Crohn's disease.

66. (currently amended) A method comprising,

- a) providing an avian egg comprising avian egg yolk and avian egg white, wherein said avian egg yolk comprises antibodies directed to human Tumor Necrosis Factor Alpha;
- b) separating said avian egg yolk from said avian egg white, and
- c) purifying said antibodies from said avian egg yolk, wherein said purifying comprises the use of polyethylene glycol.

67. (cancelled)

68. (previously presented) The method of Claim 66, wherein said avian egg comprises a chicken egg.